Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 15/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12102505 | 0.82 | SNCA (0.49) | SNCAS1PR1S1PR3S1PR5CYP2C19 | |
| SCHEMBL1293465 | 0.81 | S1PR1 (0.59) | SNCAS1PR1S1PR3CYP2C19CYP2C9 | |
| SCHEMBL2602123 | 0.78 | PDPK1 (0.41) | S1PR1S1PR3 | |
| SCHEMBL2619470 | 0.78 | S1PR1 (0.38) | S1PR1S1PR3CYP2C9XDH | |
| SCHEMBL1293023 | 0.78 | XDH (0.55) | SNCAS1PR1S1PR5CYP2C19CYP2C9 | |
| SCHEMBL1293010 | 0.78 | RXRA (0.49) | SNCAS1PR1S1PR3S1PR5CYP2C19 | |
| SCHEMBL3421493 | 0.74 | S1PR1 (0.43) | S1PR1S1PR3S1PR5CYP2C19CYP2C9 | |
| SCHEMBL3418444 | 0.72 | S1PR1 (0.49) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL12497223 | 0.71 | SNCA (0.55) | SNCACYP2C19CYP2C9 | |
| SCHEMBL2619449 | 0.71 | KDM4E (0.37) | S1PR1S1PR3S1PR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389508-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20120101083-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101136-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1- PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2012-04-26 | — | — | US | disclosed |
| US-20120101134-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120094979-A1 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20110269738-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269738-A1 | COMPOUNDS | CYP11B2, CYP11B1, GPR119 | SNCA 230/4885S1PR1 1075/4885S1PR3 1079/4885 |
| US-20120094979-A1 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | S1PR1, S1PR5, S1PR2 | SNCA 2225/4885S1PR1 1/4885S1PR3 4/4885 |
| US-20120101136-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1- PHOSPHATE RECEPTOR AGONISTS | S1PR1, S1PR5, S1PR3 | SNCA 1664/4885S1PR1 1/4885S1PR3 3/4885 |
| US-20120101134-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | S1PR1, S1PR5, S1PR3 | SNCA 1664/4885S1PR1 1/4885S1PR3 3/4885 |
| US-20120101083-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | S1PR1, S1PR2, S1PR3 | SNCA 1376/4885S1PR1 1/4885S1PR3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.